Repurposing Antimalarials to Tackle the COVID-19 Pandemic
Related Experiment Video
Updated: Dec 2, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Sanjeev Krishna1, Yolanda Augustin2, Jigang Wang3
1Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection and Immunity, St George's University of London, London, UK; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany.
Abstract:
Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
Related Concept Videos
Retrovirus Life Cycles
Antimicrobial Effectiveness

